Finance

Lists
Why is BBOT down 3,22%?
Dive Deeper
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
3,31 $
-3,22%
(-0,11) 1D
3,35 $
+1,21% (+0,040)
After hours
Closed: 9 հոկ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
3,43 $
High
3,50 $
Low
3,30 $
Mkt. cap
265,38 մլն
Avg. vol.
672,97 հզր
Volume
471,95 հզր
52-wk high
14,87 $
52-wk low
3,27 $
EPS
-3,04 $
Shares outstanding
80,17 մլն
No. of employees
88
Open
3,43 $
High
3,50 $
Low
3,30 $
Mkt. cap
265,38 մլն
Avg. vol.
672,97 հզր
Volume
471,95 հզր
52-wk high
14,87 $
52-wk low
3,27 $
EPS
-3,04 $
Shares outstanding
80,17 մլն
No. of employees
88
News stories
From web sources and news partners
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees88
Founded2016
HeadquartersSouth San Francisco, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitebbotx.com
Analyst ratings
Based on 9 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current 3,31 $
25,00 $ (+655,29%)
Average
21,00 $ (+534,44%)
Lowest
15,00 $ (+353,17%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Berens
Leerink Partners
Buy
Reiterated
25,00 $
+655,3%
09/18/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Unknown Analyst
Wedbush
Buy
Maintained
25,00 $
+655,3%
09/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
21,00 $
+534,4%
09/09/2026
Sean McCutcheon
Raymond James
Buy
Maintained
22,00 $
+564,7%
09/09/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
15,00 $
+353,2%
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
20,00 $
+504,2%
09/09/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
18,00 $
+443,8%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
25,00 $
+655,3%
08/14/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
22,00 $
+564,7%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
25,00 $
+655,3%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
22,00 $
+564,7%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
29,00 $
+776,1%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35,05 մլն
38,07 մլն
39,80 մլն
49,22 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14,13 մլն
5,33 մլն
6,38 մլն
10,96 մլն
Operating expense
49,18 մլն
43,41 մլն
46,18 մլն
60,19 մլն
Total operating expenses
49,18 մլն
43,41 մլն
46,18 մլն
60,19 մլն
Operating income
-49,18 մլն
-43,41 մլն
-46,18 մլն
-60,19 մլն
Other non operating income
980,00 հզր
187,00 հզր
129,00 հզր
182,00 հզր
EBT including unusual items
-44,76 մլն
-38,80 մլն
-42,11 մլն
-56,45 մլն
EBT excluding unusual items
-44,76 մլն
-38,80 մլն
-42,11 մլն
-56,45 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44,76 մլն
-38,80 մլն
-42,11 մլն
-56,45 մլն
Net profit margin
-
-
-
-
Earnings per share
-1,03
-0,49
-0,53
-0,71
Interest and investment income
3,44 մլն
4,42 մլն
3,94 մլն
3,55 մլն
Interest expense
-
-
-
-
Net interest expenses
3,44 մլն
4,42 մլն
3,94 մլն
3,55 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-49,11 մլն
-43,32 մլն
-46,10 մլն
-60,11 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps